UCSF and Genentech Team Up to Study Small Molecules | GenomeWeb

The University of California, San Francisco, and Roche Group subsidiary Genentech have signed an agreement to collaborate in the discovery and development of drug candidates for the treatment of neurodegenerative diseases.

Genentech will provide the funding for the venture, which will focus on small molecules to target specific proteins or enzymes, modulate biochemical or cellular processes, and have the potential to alter disease states. "Genentech is working on building its expertise in neuroscience research," says company spokeswoman Caroline Pecquet.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.